Skip to main content

Table 1 Clinical and laboratory characteristics of the patient groups

From: Increased levels of sphingosine-1-phosphate in cerebrospinal fluid of patients diagnosed with tick-borne encephalitis

Clinical group

Total number

Age

 

CSF

(Females)

(Years)

QALB

Total protein (μg/ml)

Lymphocytes

TBE-I

     

with GCs treatment

21(10)

43.7 ± 16.2

12.1 ± 1.4

851 ± 121

105 ± 15.1

without GCs treatment

24(11)

  

829 ± 129

93 ± 12.1

TBE-II

 

40.7 ± 16.9

11.3 ± 1.7

  

with GCs treatment

19(10)

  

811 ± 128

76 ± 23.4

without GCs treatment

 

44.2 ± 12.8

11.6 ± 1.3

784 ± 122

76 ± 14.1

20(9)

    

LNB

 

39.1 ± 16.7

10.8 ± 1.3

782 ± 152

48.2 ± 9.3

18(7)

46.5 ± 10.3

9.8 ± 1.1

  

MS

22(16)

37.2 ± 13.4

6.5 ± 0.9

435 ± 163

5.7 ± 4.6

Control

 

Idiopathic cephalgia

21(14)

43.6 ± 21.4

6.1 ± 0.5

414 ± 144

3.7 ± 1.9

Idiopathic (Bell’s) facial nerve palsy

16(10)

45.2 ± 18.8

6.7 ± 1.1

375 ± 183

4.1 ± 1.2

  1. QALB = albumin concentration in CSF: albumin concentration in blood. CSF - cerebrospinal fluid, TBE-I - tick borne encephalitis before treatment, TBE-II - tick borne encephalitis after 10 to 12 days of treatment, LNB - Lyme neuroborreliosis, MS - multiple sclerosis, GCs - glucocorticosteroids.